OTIC · Otonomy, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $125.0K | $273.0K | $600.0K | $683.0K | - | - |
| Cost of Revenue | $370.0K | $1.19M | $912.0K | $1.66M | - | - |
| Gross Profit | ($245.0K) | ($915.0K) | ($312.0K) | ($981.0K) | - | - |
| R&D | $34.67M | $28.00M | $32.80M | $31.84M | $42.70M | $60.72M |
| SG&A | $14.71M | $14.57M | $11.69M | $20.01M | $49.78M | $49.78M |
| Total Operating Expenses | $49.75M | $43.76M | $45.41M | $112.16M | $92.64M | $112.16M |
| D&A | $856.0K | $1.06M | $1.15M | $1.19M | $1.29M | $708.0K |
| Operating Income | ($49.63M) | ($43.49M) | ($44.81M) | ($52.05M) | ($91.40M) | ($111.48M) |
| Interest Expense | - | - | - | - | - | $0 |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $1.0K |
| Net Income | ($51.18M) | ($44.73M) | ($44.67M) | ($50.37M) | ($90.13M) | ($110.58M) |
| EPS - Basic | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $77.41M | $30.77M | $25.19M | $33.63M | $18.46M | $24.16M |
| Accounts Receivable | - | - | $48.0K | $108.0K | $107.0K | $91.0K |
| Inventory | - | $478.0K | - | - | $6.0K | $1.44M |
| Accounts Payable | $1.09M | $849.0K | $1.16M | $1.03M | $961.0K | $1.29M |
| Current Assets | $80.47M | $88.72M | $63.15M | $100.07M | $122.44M | $202.22M |
| Total Assets | $95.64M | $106.27M | $83.02M | $104.99M | $128.36M | $208.60M |
| Current Liabilities | $12.33M | $10.99M | $12.50M | $7.49M | $8.19M | $15.23M |
| Long-term Debt | $16.00M | $15.16M | $14.97M | $14.76M | - | - |
| Total Liabilities | $40.73M | $40.00M | $42.78M | $25.25M | $11.09M | $15.86M |
| Stockholders' Equity | $54.91M | $66.27M | $40.23M | $79.74M | $117.28M | $192.74M |
| Retained Earnings | ($555.80M) | ($504.62M) | ($459.89M) | ($415.22M) | ($364.85M) | ($274.72M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($42.42M) | ($38.87M) | ($36.92M) | ($94.31M) | ($75.31M) | ($94.31M) |
| Investing Cash Flow | $55.96M | ($20.21M) | $28.30M | ($149.42M) | $69.00M | ($149.42M) |
| Financing Cash Flow | $33.10M | $64.66M | $195.0K | $109.22M | $1.07M | $109.22M |
| CapEx | $295.0K | $134.0K | $700.0K | $496.0K | $1.26M | $2.55M |
| Free Cash Flow | ($42.71M) | ($39.01M) | ($37.63M) | ($94.80M) | ($76.57M) | ($96.85M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | -196.0% | -335.2% | -52.0% | -143.6% | - | - |
| Operating margin | -39700.0% | -15929.3% | -7467.8% | -7621.2% | - | - |
| EBITDA margin | -39015.2% | -15540.3% | -7276.3% | -7447.6% | - | - |
| Net margin | -40944.8% | -16385.0% | -7445.8% | -7374.5% | - | - |
| Free cash flow margin | -34170.4% | -14288.6% | -6270.8% | -13880.1% | - | - |
| FCF / Net income | 0.83 | 0.87 | 0.84 | 1.88 | 0.85 | 0.88 |
| R&D / Revenue | 27738.4% | 10255.3% | 5467.5% | 4662.4% | - | - |
| SG&A / Revenue | 11765.6% | 5338.8% | 1948.3% | 2929.4% | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -53.5% | -42.1% | -53.8% | -48.0% | -70.2% | -53.0% |
| Return on equity | -93.2% | -67.5% | -111.0% | -63.2% | -76.9% | -57.4% |
| Return on invested capital | -55.3% | -42.2% | -64.1% | -43.5% | - | - |
| Liquidity | ||||||
| Current ratio | 6.52 | 8.07 | 5.05 | 13.36 | 14.95 | 13.28 |
| Quick ratio | 6.52 | 8.03 | 5.05 | 13.36 | 14.95 | 13.18 |
| Cash ratio | 6.28 | 2.80 | 2.02 | 4.49 | 2.25 | 1.59 |
| Leverage | ||||||
| Debt / Equity | 0.29 | 0.23 | 0.37 | 0.19 | - | - |
| Debt / Assets | 0.17 | 0.14 | 0.18 | 0.14 | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.74 | 1.60 | 2.06 | 1.32 | 1.09 | 1.08 |
| Liabilities / Assets | 0.43 | 0.38 | 0.52 | 0.24 | 0.09 | 0.08 |
| Efficiency | ||||||
| Asset turnover | 0.00 | 0.00 | 0.01 | 0.01 | - | - |
| Inventory turnover | - | 2.49 | - | - | - | - |
| Days sales outstanding | - | - | 29d | 58d | - | - |
| Days inventory outstanding | - | 147d | - | - | - | - |
| Days payable outstanding | 1075d | 261d | 465d | 226d | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -54.2% | -54.5% | -12.2% | - | - | - |
| Revenue CAGR (3y) | -43.2% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | 73.2% | -193.3% | 68.2% | - | - | - |
| Operating income growth (YoY) | -14.1% | 2.9% | 13.9% | 43.0% | 18.0% | -79.9% |
| Net income growth (YoY) | -14.4% | -0.1% | 11.3% | 44.1% | 18.5% | -79.3% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -9.5% | -3.7% | 60.3% | -23.8% | 20.9% | -86.6% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -17.1% | 64.7% | -49.5% | -32.0% | -39.2% | 6.2% |
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-5.46
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing OTONOMY against the 5 most active filers in the same SIC group.